153 related articles for article (PubMed ID: 32862133)
1. Cytosine arabinoside constant rate infusion without subsequent subcutaneous injections for the treatment of dogs with meningoencephalomyelitis of unknown origin.
Stee K; Broeckx BJG; Targett M; Gomes SA; Lowrie M
Vet Rec; 2020 Nov; 187(11):e98. PubMed ID: 32862133
[TBL] [Abstract][Full Text] [Related]
2. Effect of a constant rate infusion of cytosine arabinoside on mortality in dogs with meningoencephalitis of unknown origin.
Lowrie M; Thomson S; Smith P; Garosi L
Vet J; 2016 Jul; 213():1-5. PubMed ID: 27240905
[TBL] [Abstract][Full Text] [Related]
3. Corticosteroid monotherapy versus combined cytarabine continuous rate infusion and corticosteroid therapy in dogs with meningoencephalitis of unknown origin: A blinded, randomized, controlled trial.
Jones BS; Liebel FX; Fadda A; Martin S; Lawn R; Lazzerini K; Harcourt-Brown T
J Vet Intern Med; 2024; 38(3):1618-1625. PubMed ID: 38700360
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of a cytosine arabinoside subcutaneous protocol in dogs with meningoencephalomyelitis of unknown aetiology.
Levitin HA; Foss KD; Li Z; Reinhart JM; Hague DW; Fan TM
J Vet Pharmacol Ther; 2021 Sep; 44(5):696-704. PubMed ID: 34080695
[TBL] [Abstract][Full Text] [Related]
5. Treatment With Cytarabine at Initiation of Therapy With Cyclosporine and Glucocorticoids for Dogs With Meningoencephalomyelitis of Unknown Origin Is Not Associated With Improved Outcomes.
Barber R; Downey Koos L
Front Vet Sci; 2022; 9():925774. PubMed ID: 35754543
[TBL] [Abstract][Full Text] [Related]
6. Plasma and serum concentrations of cytarabine administered via continuous intravenous infusion to dogs with meningoencephalomyelitis of unknown etiology.
Early PJ; Crook KI; Williams LM; Davis EG; Muñana KR; Papich MG; Messenger KM
J Vet Pharmacol Ther; 2017 Aug; 40(4):411-414. PubMed ID: 27641693
[TBL] [Abstract][Full Text] [Related]
7. The pharmacokinetics of cytarabine administered at three distinct subcutaneous dosing protocols in dogs with meningoencephalomyelitis of unknown origin.
Jones A; McGrath S; Gustafson DL
J Vet Pharmacol Ther; 2019 Nov; 42(6):588-592. PubMed ID: 31490575
[TBL] [Abstract][Full Text] [Related]
8. Treatment of 11 dogs with meningoencephalomyelitis of unknown origin with a combination of prednisolone and cytosine arabinoside.
Menaut P; Landart J; Behr S; Lanore D; Trumel C
Vet Rec; 2008 Feb; 162(8):241-5. PubMed ID: 18296666
[TBL] [Abstract][Full Text] [Related]
9. The pharmacokinetics of cytarabine in dogs when administered via subcutaneous and continuous intravenous infusion routes.
Crook KI; Early PJ; Messenger KM; Muñana KR; Gallagher R; Papich MG
J Vet Pharmacol Ther; 2013 Aug; 36(4):408-11. PubMed ID: 22943060
[TBL] [Abstract][Full Text] [Related]
10. Clinical presentation, diagnostic findings, prognostic factors, treatment and outcome in dogs with meningoencephalomyelitis of unknown origin: A review.
Cornelis I; Van Ham L; Gielen I; De Decker S; Bhatti SFM
Vet J; 2019 Feb; 244():37-44. PubMed ID: 30825893
[TBL] [Abstract][Full Text] [Related]
11. The pharmacokinetics of cytarabine administered subcutaneously, combined with prednisone, in dogs with meningoencephalomyelitis of unknown etiology.
Pastina B; Early PJ; Bergman RL; Nettifee J; Maller A; Bray KY; Waldron RJ; Castel AM; Munana KR; Papich MG; Messenger KM
J Vet Pharmacol Ther; 2018 Oct; 41(5):638-643. PubMed ID: 29761906
[TBL] [Abstract][Full Text] [Related]
12. Combined cytosine arabinoside and prednisone therapy for meningoencephalitis of unknown aetiology in 10 dogs.
Zarfoss M; Schatzberg S; Venator K; Cutter-Schatzberg K; Cuddon P; Pintar J; Weinkle T; Scarlett J; Delahunta A
J Small Anim Pract; 2006 Oct; 47(10):588-95. PubMed ID: 17004951
[TBL] [Abstract][Full Text] [Related]
13. Meningoencephalitis of unknown origin: investigation of prognostic factors and outcome using a standard treatment protocol.
Lowrie M; Smith PM; Garosi L
Vet Rec; 2013 May; 172(20):527. PubMed ID: 23462382
[TBL] [Abstract][Full Text] [Related]
14. Survival time and relapse in dogs with meningoencephalomyelitis of unknown origin treated with prednisolone and ciclosporin: a retrospective study.
Brady SL; Woodward AP; le Chevoir M
Aust Vet J; 2020 Oct; 98(10):491-498. PubMed ID: 32794230
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of treatment with a combination of mycophenolate mofetil and prednisolone in dogs with meningoencephalomyelitis of unknown etiology: a retrospective study of 86 cases (2009-2017).
Song JH; Yu DH; Lee HC; Hwang TS; Kim YJ; An SJ; Jung DI
BMC Vet Res; 2020 Jun; 16(1):192. PubMed ID: 32532259
[TBL] [Abstract][Full Text] [Related]
16. Clinical presentation, diagnostic findings and outcome in dogs diagnosed withpresumptive spinal-only meningoen-cephalomyelitis of unknown origin.
Cornelis I; Volk HA; Van Ham L; De Decker S
J Small Anim Pract; 2017 Mar; 58(3):174-182. PubMed ID: 28267222
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid and blood lactate concentrations as prognostic biomarkers in dogs with meningoencephalitis of unknown origin.
Portero M; Martínez de Merlo E; Pérez C; Benito M; Daza MA; Fragio C
Vet J; 2019 Dec; 254():105395. PubMed ID: 31836169
[TBL] [Abstract][Full Text] [Related]
18. Perspectives on meningoencephalomyelitis of unknown origin.
Coates JR; Jeffery ND
Vet Clin North Am Small Anim Pract; 2014 Nov; 44(6):1157-85. PubMed ID: 25239815
[TBL] [Abstract][Full Text] [Related]
19. Retrospective evaluation of prognosis and survival with various immunosuppressants in 82 dogs diagnosed with meningoencephalitis of unknown etiology (2010-2021).
Kim SH; Oh YI; Park SM; An JH; Kim TH; Kim SS; Ah JG; Seo KW; Youn HY
BMC Vet Res; 2023 Dec; 19(1):269. PubMed ID: 38087262
[TBL] [Abstract][Full Text] [Related]
20. Comparison of two regimens for the treatment of meningoencephalomyelitis of unknown etiology.
Smith PM; Stalin CE; Shaw D; Granger N; Jeffery ND
J Vet Intern Med; 2009; 23(3):520-6. PubMed ID: 19645837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
